Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Hareth Nahia Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, SwedenCorrespondence[email protected]
View further author information

Saad Z. Usmanib Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information

Maria-Victoria Mateosc University Hospital of Salamanca/IBSAL/Cancer Research Center – IBMCC (USAL-CSIC), Salamanca, Spain

Niels W. C. J. van de Donkd Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The NetherlandsView further author information

Albert Oriole Institut Català d‘Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, SpainView further author information

Torben Plesnerf Vejle Hospital and University of Southern Denmark, Vejle, DenmarkView further author information

Nibedita Bandyopadhyayg Janssen Research & Development, LLC, Spring House, PA, USAView further author information

Peter Hellemansh Janssen Research & Development, Beerse, BelgiumView further author information

Brenda Trompi Janssen Research & Development, LLC, Leiden, The NetherlandsView further author information

Ivo Nnaneg Janssen Research & Development, LLC, Spring House, PA, USAView further author information

Donna Zemlickisj Janssen Research & Development, LLC, Toronto, Ontario, CanadaView further author information

Ajai Charik Icahn School of Medicine at Mount Sinai, New York, NY, USA

Philippe Moreaul Hematology Department, University Hospital Hôtel-Dieu, Nantes, FranceView further author information

Your download is now in progress and you may close this window